Biopharmaceutical companies are reducing drug development timelines by integrating genomics-driven biomarker profiling into early-stage research. The methodological shift increases candidate selection accuracy while narrowing patient trial cohorts.
Trial Optimization Impact
Data from recent oncology trials indicates a 35% reduction in phase II failure rates when biomarker selection criteria are applied. The approach allows research firms to allocate capital efficiently toward high-probability candidate molecules.